Johnson & Johnson Releases Single-Dose Vaccine Results

Johnson & Johnson announced on Friday that its coronavirus vaccine was 72 percent effective against the pathogen in the U.S., and the company will ask federal regulators for approval in February.

Unlike the Pfizer-BioNTech and Moderna candidates, Johnson & Johnson’s vaccine is administered in one shot. The vaccine uses a relatively new technology to deliver a coronavirus gene into the body by using a modified form of the common cold. The gene instructs bodily cells to make a protein similar to coronavirus, which wards off infection.